CPHI Barcelona is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Awards
24 Oct 2023 • Fira Barcelona Gran Via, Barcelona, Spain
Entry deadline
31 May 2023
Why enter?
The annual CPHI Pharma Awards celebrate the teams, individuals and companies whose products and solutions enable purposeful change within our industry.
The CPHI Pharma Awards are free to enter and open to pharmaceutical and biopharmaceutical companies across the global pharma supply chain.
You don't need to be an exhibitor at CPHI Barcelona to enter, and you may submit multiple entries across all categories.
All entries must be based on activities undertaken between 30 May 2022 – 1 August 2023 (See criteria for full eligibility details).
You can resubmit entries multiple times before the final deadline. We advise you not to leave your submission until the last minute. Selected finalists will be notified individually in September.
Discover the companies in line for the prize!
This year’s shortlist will be revealed on the 4th of September. Finalists will be notified individually.
A glamorous drinks reception kicks off the award ceremony at the end of day 1 at Fira Barcelona, where we announce the winners and celebrate each of their achievements.
This year, the CPHI Pharma Awards will recognise excellence across the following categories:
Recognising innovation in technologies, products, processes, and services to combat the impact of global healthcare emergencies on individuals, patients, healthcare professionals and communities. Including but not limited to drug or device development, rapid response, medical equipment and the introduction of services, solutions and resources to combat the impact of past and potential healthcare emergencies.
Criteria:
Innovation
How does the entry demonstrate innovation and resourcefulness in response to healthcare emergencies? Will it inspire future development?
Purpose and Outcomes
Does it achieve its purpose? Does it offer benefits to the audience it was designed for?
Problem-solving
Does the entry demonstrate a unique approach to solving a particular challenge?
Competitive Advantage
How does the entry demonstrate going above and beyond or a collaborative approach in a time of crisis?
Innovation in technologies, products, processes, and services for the development and manufacture of active pharmaceutical ingredients including, but not limited to, synthesis, characterization, scale-up, software and database development, bulk manufacturing.
Criteria:
Innovation
Does the entry introduce a new idea, method or process to the market? Will it inspire broader applications?
Purpose
Does it achieve its purpose? Does it offer clear benefits or improvements over existing solutions?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Innovation in technologies, products, processes, and services related to the formulation of drug products including, but not limited to, excipients, finished dose, OTC, novel software and digitilisation, process development, resolving formulation challenges, bioavailability enhancement, drug targeting or controlled release and stabilization technologies.
Please note: to be eligible for this category, the activity must have taken place between Jan 2022 - August 2023.
Criteria
Innovation
Does the entry introduce a new idea, method, or novelty to the market?
Purpose
Does it achieve its purpose? Does it offer clear benefits or improvements over existing solutions?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Innovation in technologies, processes, and services for the manufacture of solid, semi-solid, parenteral, inhalation, or other dosage drugs including, but not limited to, equipment, approaches,digitilisation, manufacturing processes, facilities, tech transfer and process controls. We welcome entries across both small and large molecule manufacturing.
Criteria
Innovation
Does the entry introduce a new idea, process, method, or novelty to the market? Will it inspire future development?
Features
Does the entry have unique qualities, abilities, or significantly improved attributes?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Innovation in technologies, products, solutions, processes, and services related to drug delivery, routes of administration and device innovation. Including, but not limited to, inhalers, auto-injectors, pre-filled syringes, patches, combination products, intelligent packaging and connected devices.
Criteria
Innovation
Does the entry introduce a new idea, device, method or novelty to the market? Will it inspire future development?
Features & Purpose
Does the entry have unique qualities, abilities, or improved attributes? Does it offer a significant improvement on existing market solutions?
Patient Centricity
Does the entry offer tangible improvements to patient adherence and experience?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Innovation in technologies, products, processes, equipment and services for primary, secondary and tertiary packaging solutions and the packaging and assembly of finished drug products. Including but not limited to, vials, ampules, blister packs, cartons, containers, tamper-proof packaging, labelling systems, track and trace, machinery, anticounterfeiting measures and solutions which prioritise patient centricity and adherence.
Criteria
Innovation
Does the entry introduce a new idea, device, method, or service to the market? Will it inspire future development?
Purpose
Does it achieve what it was intended to achieve? Does it offer a significant improvement on existing market solutions?
Sustainability
Has the entry been created with sustainability in mind? Does it seek to reduce carbon emissions or environmental impact?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Innovation in technologies, products, processes, and services for ensuring the safe handling, security and tracking of drug substances, raw materials, and finished drug products. Including, but not limited to, supply chain optimisation, audits, temperature-controlled logistics, transport services, shipping and storage, anticounterfeiting, inventory management, demand forecasting and distribution channels.
Criteria
Innovation
Does the entry introduce a new idea, device, method, or service to the market? Will it inspire future development?
Purpose
Does it achieve what it was intended to achieve? Does it offer a significant improvement on existing market solutions?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Recognition of sustainable manufacturing, production or development in the pharmaceutical industry. Including but not limited to, innovative approaches to reducing environmental impact, waste and carbon emissions, energy or utility saving solutions, sustainable and collaborative product development, plastic reduction, improved recyclability or lifecycle management, implementation of circular economy initiatives, innovative use of materials, safeguarding of workers, and programmes or initiatives which seek to improve diversity and inclusion.
Criteria
Innovation
Does the entry introduce a new idea, material, device, method, or service to the market? Will it inspire future development?
Purpose
Does it achieve what it was intended to achieve? Does it offer a proven improvement on existing market solutions?
Environmental Impact
Does the entry offer a demonstrable improvement in reducing carbon emissions?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
Innovation in technologies, products, processes, and services designed to aid and ensure compliance with standards, mandates, and guidance documents established by regulatory authorities.Including, but not limited to, consulting services, development of consortia and industry groups, reference standards, educational programs, case studies, technologies, platforms and equipment.
Criteria
Innovation
Does the entry introduce a new idea, method, or service to the market? Will it inspire future development?
Process Excellence
Does the entry offer an improved process, leading to better outcomes and results?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Competitive Advantage
Does it offer a competitive advantage in the market and within its category?
C-Suite Executives of SME, Large Pharma/Biopharma or service providers are eligible for nomination. Attributes to be considered include, but are not limited to, financial performance, product performance, global reach, leadership skills, management capability, charitable initiatives, sustainability, regulatory compliance, profitability, vision, marketing, acquisitions, corporate strategy, and financing.
Criteria
Dynamism
Is the nominee an exemplary leader with a strong desire to achieve – are they compelling and progressive? How have they demonstrated exceptional leadership?
Achievements
Has the CEO achieved or accomplished sustained growth, improved performance, implemented robust strategies, engaged staff and customers in their current role or throughout the course of their career?
Leadership
Has the CEO demonstrated consistent personal strengths and attributes that makes them an extraordinary leader?
Contribution to the Wider Industry
Is the CEO committed to the development of the broader pharma industry – this could involve donating goods, funding, time, market insights business intelligence, or contributing to educational programmes.
A new category for 2023, the Start-Up Initiative award seeks to recognise Start-Ups and SMEs driving value and innovation across the pharma value chain. We are looking for entries which demonstrate a clear promise of innovation, growth or sustainable development in pharma.
We understand that Start-Ups are often at different stages of development, and accept entries across proof of concept, protype or commercialised stage.
Entries are reserved exclusively for organisations participating in the CPHI Start-Up Market. [If you are a Start-Up who would like to take part, please visit the Start-Up Brochure for more information]
Criteria
Innovation
Does the entry introduce a new idea, device, method or service to the market? Does it drive or facilitate efficiencies?
Industry disruptor
Does this product have the potential to disrupt the industry or become the future benchmark for innovation and change?
Sustainability
Is this product created with sustainability in mind? Does it aim to reduce carbon emissions, waste or environmental impact?
Patient centricity
Does the product or solution offer a significant improvement or development for patients and end users?
This award looks to recognise companies, individuals and initiatives which nurture philanthropic, ethical and community-based ventures. We welcome entries which prioritise patient engagement and centricity, promote corporate social responsibility and improve healthcare accessibility or equity.
Criteria:
Innovation
Does the entry introduce a new idea, method, or service to the market?
Contribution to the Wider Industry
Does the entry demonstratea commitment to improving the pharma industry? Will it inspire future development?
Problem-solving
Does it solve a problem? Does it address an issue in an effective way?
Outcomes
Can the entry demonstrate sufficient evidence of improved outcomes, through data, case studies or testimonials?
Submit your entry today and set the industry standard. The awards are free to enter, and we welcome entries across multiple categories.
The CPHI Pharma Awards prides itself on its judging panel. These independent industry experts from around the world have been specially chosen for their knowledge, credentials and objectivity.
Thomas Kern
VINC – The Capital Of Life
Founder and Managing Partner
Christophe Jauquet
Healthusiasm
Keynote speaker and health business expert
Mayur Patel
PA Consulting
Medical Device Innovation Expert
Orlaith Ryan
Shorla Pharma
Co-Founder / CEO
Anita Vasilevska
IMCD
Technical Marketing Manager
Wayne Weiner
Pharmatech Solutions
President
Fiona Barry
GlobalData
Editor - Pharmasource
Enric Bosch
Boehringer Ingleheim
Senior EHS Manager - Supplier Qualification and Auditing
Harsh Chauhan
Creighton University
Assistant Professor
Emil Ciurczak
Doramaxx Consulting
President
Bikash Chatterjee
Pharmatech Associates
President and Chief Scientific Officer
Duncan Emmerton
Informa Pharma Intelligence
Consultant - Informa Pharma Intelligence
Pascale Gauthier
Auvergne University
Pharmacist, PhD
Vincent Galand
Auvergne University
Pharmacist, PhD
Sanobar Syed
Beigene Ltd
Associate Director- Market Insights and Strategy
Phillip Broadwith
Chemistry World
Business Editor
Answers to some of the most common queries
We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy and Cookie Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.